Kamada (NASDAQ:KMDA) Coverage Initiated by Analysts at Benchmark

Benchmark initiated coverage on shares of Kamada (NASDAQ:KMDA) in a research report released on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $15.00 target price on the biotechnology company’s stock.

A number of other brokerages have also recently issued reports on KMDA. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research note on Thursday, March 6th. StockNews.com raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 13th.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $6.72 on Friday. The firm has a fifty day moving average price of $7.19 and a 200-day moving average price of $6.26. The stock has a market cap of $386.27 million, a PE ratio of 24.00, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. Kamada has a 1 year low of $4.74 and a 1 year high of $9.16.

Kamada Announces Dividend

The business also recently declared a — dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Monday, March 17th.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the last quarter. Aristides Capital LLC increased its holdings in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Kamada in the 4th quarter valued at $67,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Kamada in the 3rd quarter valued at $77,000. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.